Autologous bone marrow-derived mononuclear cells transplantation in type 2 diabetes mellitus: effect on β-cell function and insulin sensitivity

• Published in: Diabetology and metabolic syndrome 2017-07, Vol.9 (1), p.50-50, Article 50
• Main Authors: Bhansali, Shobhit, Dutta, Pinaki, Yadav, Mukesh Kumar, Jain, Ashish, Mudaliar, Sunder, Hawkins, Meredith, Kurpad, Anura V, Pahwa, Deepak, Yadav, Ashok Kumar, Sharma, Ratti Ram, Jha, Vivekanand, Marwaha, Neelam, Bhansali, Shipra, Bhansali, Anil
• Format: Article
• Language: English
• Subjects: Autologous bone marrow-derived mononuclear cells; Short Report; Stem cells; T2DM
• ISSN: 1758-5996; 1758-5996
• DOI: 10.1186/s13098-017-0248-7

Insulin resistance and insulin deficiency are the cardinal defects in the pathogenesis of type 2 diabetes mellitus (T2DM). Despite the plethora of anti-diabetic medications, drugs specifically targeting the β-cells are still desired. Stem cell therapy has emerged as a novel therapeutics strategy to target β-cells; however, their mechanism of action has not been well defined. This study aims to examine the efficacy and safety of autologous bone marrow-derived mononuclear cells (ABM-MNCs) transplantation in T2DM, and explores the mechanistic insights into stem cells action through metabolic studies. Seven T2DM patients with the duration of disease ≥5 years, receiving triple oral anti-diabetic drugs along with insulin (≥0.4 IU per kg per day) and HbA1c ≤ 7.5% (≤58.0 mmol/mol) were enrolled for ABM-MNCs administration through a targeted approach. The primary end-point was a reduction in insulin requirement by ≥50% from baseline, while maintaining HbA1c